|Application ||WB, E|
|Other Accession||NP_001129386, 209571519|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||159938 Da|
|Application Notes||CRIM2 antibody can be used for detection of CRIM2 by Western blot at 1 - 2 µg/mL.|
|Target/Specificity||KCP; At least two isoforms of CRIM2 are known to exist; this antibody will only detect the larger isoform. CRIM2 antibody is predicted to not cross-react with CRIM1.|
|Reconstitution & Storage||CRIM2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||CRIM2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Enhances bone morphogenetic protein (BMP) signaling in a paracrine manner. In contrast, it inhibits both the activin-A and TGFB1-mediated signaling pathways (By similarity).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CRIM2 Antibody: CRIM2, also known as Kielin/chordin-like protein (KCP), is a novel enhancer of BMP signaling. It binds to BMP7, a morphogen that is important for kidney development and part of the kidney's physiological response to repair of acute kidney injury, enhancing its binding to its receptor. Because of this, CRIM2 has been suggested as a potential antifibrotic therapy in acute and chronic kidney injury. CRIM2 can also interact directly with either activin or TGF-β1, suppressing activin- and TGF-β1-dependent transcription.
Lin J, Patel SR, Cheng X, et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 2005; 11:387-93
Zeisberg M and Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr. Nephrol. 2008; 23:1395-8.
Lin J, Patel SR, Wang M, et al. The cysteine-rich domain protein KCP is a suppressor of transforming growth factor β/Activin signaling in renal epithelia. Mol. Cell. Biol. 2006; 26:4577-85.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.